Leadership changeCompany-reported
What was reported
DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 28, 2026 · Open the source ↗
What the evidence supports
Humacyte told the SEC (Form 8-K, Item 5.02) that there was a change involving its directors or officers, or their pay arrangements. The filing gives Sep 22, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
The reasons for the change beyond those stated, and what it means for the company's strategy or results.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineHumacyte Expands Board Expertise with Appointment of Scott Coward and Paul KuznikU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 28, 2026 · Open the source ↗
Press release lead paragraphDURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 28, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.